CareDx (NASDAQ:CDNA - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect CareDx to post earnings of $0.07 per share and revenue of $84.56 million for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Shares of CDNA opened at $24.49 on Wednesday. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -9.07 and a beta of 1.87. CareDx has a 1-year low of $7.42 and a 1-year high of $34.84. The company's fifty day simple moving average is $22.69 and its 200 day simple moving average is $25.41.
A number of equities analysts recently weighed in on the stock. BTIG Research lowered their target price on shares of CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, November 5th. Wells Fargo & Company upgraded shares of CareDx from an "underweight" rating to an "equal weight" rating and lowered their target price for the stock from $28.00 to $24.00 in a report on Wednesday, January 15th. StockNews.com cut shares of CareDx from a "buy" rating to a "hold" rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $26.00 price objective on shares of CareDx in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $28.33.
View Our Latest Stock Report on CDNA
In related news, Director Peter Maag sold 5,000 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the sale, the director now owns 330,024 shares of the company's stock, valued at $8,250,600. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.90% of the stock is currently owned by company insiders.
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.